Presented by Andrew Guinigundo,(1) MSN, RN, CNP, ANP-BC, FAPO, and Grace Baek,(2) PharmD, BCOP
There has been an increasing number of approvals for targeted therapies in oncology in the past decade, changing the treatment paradigm for many solid tumors and hematologic malignancies. At JADPRO Live 2023, presenters provided an in-de...
Presented by Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
At JADPRO Live 2023 in Orlando, Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP, briefed advanced practitioners on key US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Holle described indications, mechanisms of actio...
At JADPRO Live 2023 in Orlando, Rebecca L. Rezac, PharmD, BCOP, summarized key information on US Food and Drug Administration approvals from late 2022 to late 2023. Dr. Rezac described indications, mechanisms of action, and monitoring an...
Presented by Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP
During JADPRO Live 2023, Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Cuellar highlighted new drug classes, novel mechanisms of action, and safety profiles...
Presented by Stephanie L. Graff,(1,2) MD, FACP, FASCO, Christine McGinn,(1) MSN, APRN, ACNP-BC, and Jeanine R. Showalter,(3) MSN, APRN, FNP-BC, AOCNP®
At JADPRO Live 2023, presenters discussed recent updates to clinical practice in metastatic HER2-positive metastatic breast cancer. During the session, they reviewed review recent FDA approvals, the clinical relevance of HER2-low status,...
Presented by Tajuana Bradley,(1) MSN, APRN-BC, and Beth Sandy,(2) MSN, CRNP, FAPO
At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecu...
Presented by Mary B. Morgan,(1) MSN, ANP-BC, AOCN®, and Tammy Triglianos,(2) DNP, ANP-BC, AOCNP®
At JADPRO Live 2023, presenters emphasized the importance of increasing colorectal cancer screening in high-risk groups, reviewed guidelines in the adjuvant and metastatic setting, and outlined clinical and molecular profiles to consider...
Presented by Jessica Deinert, MSN, APRN, FNP-C, AOCNP®, and Leah K. Shaw, MSN, APRN, AGPCNP-BC
At JADPRO Live 2023 in Orlando, presenters provided an overview of best practices in the diagnosis, classification, and management of patients with localized and metastatic prostate cancer. They covered selecting appropriate therapies ba...
Presented by Beth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD
At JADPRO Live 2023 in Orlando, presenters discussed selecting treatment regimens for newly diagnosed and relapsed or refractory multiple myeloma. They also provided insights on comprehensive care centered around patient preferences, tre...
Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, of Cincinnati Cancer Advisors, discusses the effect of Medicaid expansion on racial disparities in mortality among patients with gastrointestinal malignancies. He also describes the phase III D...
Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the us...
Oxana Megherea, PharmD, BCOP, of the Hospital of the University of Pennsylvania, discusses the MonumenTAL-1 study of talquetamab in relapsed/refractory multiple myeloma. She also summarizes a subgroup analysis of elderly patients enrolle...
Presented by Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO, Sandra E. Kurtin,(2) PhD, ANP-C, AOCN®, FAPO, and Rasheda Persinger,(3) MSN, AGNP-C, AOCNP®
In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biom...
During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanis...
During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr....
Presented by Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechani...
Presented by Narjust Florez (Duma), MD, and Stephanie McDonald, NP
The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from ...
Presented by Marcie Beasley, FNP-C, AOCNP®, and Brooke Daniel, MD
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters di...
Presented by Cesar Rodriguez, MD, and Donna Catamero, ANP-BC, OCN®, CCRC
Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations th...
Presented by Brianna Hoffner,(1) MSN, ANP-BC, AOCNP®, FAPO, Leslie C. Appiah,(2) MD, Alexis C. Geppner,(3) MLS, CTTS, MPAS, PA-C, Laxmi A. Kondapalli,(4) MD, MSCE, and Govind Persad,(5) JD, PhD
The incidence of cancers such as colorectal cancer, head and neck cancer, and melanoma has increased in younger patients. The number of cancer survivors is also increasing in the US. Pairing these facts together, there are many people wi...
Presented by Rose DiMarco,(1) PharmD, BCPS, BCOP, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, and Caressa Valdueza,(3) MSN, AGNP-C
Implicit bias affects patient care every day, and not just in oncology. It impacts decision-making in already vulnerable populations such as the historically marginalized racial and ethnic groups, the LGBTQI+ population, patients with di...
Presented by Kyle C. Molina, PharmD, BCIDP, AAVHIP
Managing infection in patients with neutropenia is a difficult challenge, as fever is often the only clinical symptom. At JADPRO Live 2022, Kyle C. Molina, PharmD, BCIDP, AAVHIP, of the University of Colorado Hospital, discussed the epid...
At JADPRO Live 2022, Jonathan Treem, MD, of the University of Colorado Palliative Care, explained medical aid in dying in order to prepare advanced practitioners to feel confident to counsel a patient who inquiries about aid in dying. He...
Presented by Keri Halsema, NP, and Brandon McMahon, MD
The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to pro...
Presented by Holly Chitwood, DNP, APRN, FNP, AGACNP, and Tamara Carey, MSN, APRN, FNP
Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types withou...
Thirty-six clinical posters focused on the role of the advanced practitioner were presented at JADPRO Live this past October 20 to 23, 2022, in Aurora, Colorado. View the poster listing here, and access the abstracts, posters, and audio ...
Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of the Medical College of Wisconsin Cancer Center, comments on MET and CTLA-4 inhibitors for clear cell renal cell carcinoma, maintenance targeted therapy for patients with metastatic urothelial carci...
Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital/Brown University, interprets data presented at the 2022 ASCO Annual Meeting on rucaparib maintenance in advanced ovarian cancer, single-agent trabectedin in BRCA-positive ova...
Suzanne McGettigan, MSN, CRNP, AOCN®, of Abramson Cancer Center of the Hospital of the University of Pennsylvania, reviews data on adjuvant therapy in stage IIB or IIC melanoma and omitting lymph node dissection and adjuvant therapy in p...
Heidi Mason, DNP, ACNP-BC, of the University of Michigan School of Nursing, considers research on avoiding concurrent chemotherapy in patients with nasopharyngeal carcinoma being treated with radiotherapy and a clinical trial on concurre...
P. Andrew Allred, MS, PA-C, Amy Pierre, MSN, ANP-BC, Meredith Beaton, MSN, RN, Pamela Lee, NP, MSN, and Amber Koehler, PA-C
P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, considers data on managing newly diagnosed MM and CAR T-cell therapy in MM. Amy Pierre, MSN, ANP-BC, of MSKCC and Flatiron Health, reviews findings on telemedicine inequiti...
Elizabeth Koselke, PharmD, BCOP and Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP®
Elizabeth Koselke, PharmD, BCOP, of The US Oncology Network, describes a clinical pharmacist intervention to screen patients and improve clinical trial enrollment. Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP®, of the University of Haw...
Jacquelyn Lauria, RN, APN, AOCNP® and Rose DiMarco, PharmD, BCPS, BCOP
Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast can...
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews research in thoracic cancers presented at the 2022 ASCO Annual Meeting, including neoadjuvant immunotherapy for resectable stage IIIA non–small cell lung ...
Nina N. Grenon, DNP, AGCNP-BC, AOCN® and Kristen O’Hagan, MSN, ANP-BC, AOCNP®
Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on RAS wild-type metastatic colorectal cancer, locally advanced mismatch repair–deficient rectal cancer, circulating tumor DNA tests, pancreatic neuroe...
Jennifer Jacky,(1) MSN, ARNP, AOCNP®, Kristin DeGroot,(2) PA-C, and Rebecca Denney,(2) PA-C
During JADPRO Live Virtual 2021, three advanced practitioners—in surgery, radiation oncology, and medical oncology—discussed their collaboration in the management of resectable early-stage non–small cell lung cancer. The presenters discu...
R. Donald Harvey,(1) PharmD, BCOP, FCCP, FHOPA, Aaron Begue,(2) MS, RN, NP-C, Caleb Raine,(1) PA-C, and Robin Yabroff,(3) PhD, MBA
At the opening session of JADPRO Live Virtual 2021, panelists shared creative responses to the COVID-19 pandemic and considered strategies to effectively respond to crises that may impact cancer patients and practices in the future.
by Maimah Karmo,(1) and Amy Pierre,(2),(3) MSN, ANP-BC
At the JADPRO Live Virtual 2021 keynote interview, Maimah Karmo, CEO and Founder of the Tigerlily Foundation, spoke with Amy Pierre, MSN, ANP-BC, on her breast cancer experience and drive to establish an organization that educates, advoc...
The leadership journey is often a long and winding road, with speed bumps and unexpected turns. During this session of JADPRO Live Virtual, presenters discussed the leadership qualities that they have found integral, including emotional ...
Burnout has been prevalent since before COVID-19 and continues to affect a large portion of the health-care workforce. At JADPRO Live Virtual 2021, Margaret Leddy, PA-C, MMSc, defined burnout in the setting of the oncology/hematology adv...
The COVID-19 pandemic has only further brought to light how racism, bias, and lack of equity can result in social injustice, morbidity, and mortality. A panel of four advanced practitioners convened at JADPRO Live Virtual 2021 to examine...
At JADPRO Live Virtual 2021, Colleen Lewis, MSN, ANP-BC, AOCNP®, discussed the trajectory of the advanced practitioner role in clinical research, including the historical experience, potential barriers to practice, and future possibiliti...
Rose DiMarco,(1) PharmD, BCPS, BCOP, and Lisania Milli,(2) MSN, RN, WHNP-BC
The data show that racial and ethnic minority groups throughout the United States experience higher rates of illness and death across a wide range of health conditions when compared to their White counterparts. This session at JADPRO Liv...
Joan Okasako,(1) MSN, FNP-BC, RN, AOCNP®, and Carolyn Bernstein,(2) MSN, FNP-BC, RN
The history of multidisciplinary tumor boards extends to more than 50 years ago. At JADPRO Live Virtual 2021, presenters discussed the evidence-based impact of tumor boards on patient outcomes and patient-centered care, reviewed benefits...
Along with the fast pace of oncology drug approvals is the heightened opportunity for drug-drug, drug-food, and drug-herbal interactions. Attendees at the JADPRO Live Virtual 2021 conference learned about the pharmacodynamic and pharmaco...
At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy....
Patients with comorbid mental health and substance use disorders are at greater risk for mortality and have higher cancer care costs. At JADPRO Live Virtual 2021, Lisa W. Goldstone, MS, PharmD, BCPS, BCPP, talked through general consider...
As cancer care advances, creative uses for immunotherapy continue to be developed, but it is also important to be cognizant of the risk for infusion reactions. At JADPRO Live Virtual 2021, Carrie Peterson, DNP, RN, AGNP-c, reviewed the d...
Patients with cancer are at high risk for developing cancer-associated blood clots. Mailey L. Wilks, DNP, APRN, NP-C, led a session at JADPRO Live Virtual 2021 on the risk of venous thromboembolism in patients with cancer, available anti...
Advanced practitioners are often in charge of planning and implementing care for cancer survivors, as noted by Carrie Tompkins Stricker, PhD, RN, ANP-BC, during JADPRO Live Virtual 2021. During a session at the conference, Dr. Stricker r...
Many cancer patients report the use of supplements and herbal medicines but may not always disclose their use to their health-care team. Along with potential interactions, these therapies may also affect outcomes of treatment. During JAD...
Cara Fleming, AGPCNP-BC, AOCNP®, and Deirdre Kelly, AGACNP-BC
An oncology urgent care clinic can improve patient satisfaction, reduce emergency room visits, and lower health-care costs for patients and facilities. At a session taking place at JADPRO Live Virtual 2021, presenters on the frontlines o...
Undergoing surgery is one of the greatest physical and emotional challenges a patient can face, and doing so without preparation can lead to increased complications and mortality. At JADPRO Live Virtual 2021, Paul Wischmeyer, MD, EDIC, F...
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their advers...
During JADPRO Live Virtual 2021, Kirollos Hanna, PharmD, BCPS, BCOP, discussed the label indications of drugs and biologics in hematologic malignancies approved from late 2020 to late 2021, including mechanisms of action and various safe...
During JADPRO Live Virtual 2021, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mecha...
Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Haleigh Mistry,(3) MS, PA-C
In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determi...
Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®
At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the curren...
Beth Sandy,(1) MSN, CRNP, and Jennifer Morrissette,(2) PhD, FACMG
A vital role of the advanced practitioner is to analyze biomarker testing reports and explain to patients how the results may impact their treatment. At JADPRO Live Virtual 2021, presenters reviewed the importance of molecular testing in...
Pelin Cinar, MD, MS, and Patricia Zendejas, MSN, ANP-C, AOCNP®
At JADPRO Live Virtual 2021, presenters reviewed the epidemiology of pancreatic cancer, treatment options for patients with different stages of pancreatic cancer, and the most common symptoms and complications related to pancreatic cance...
Kirollos S. Hanna,(1) PharmD, BCPS, BCOP, and Zita D. Lim,(2) PA-C
At JADPRO Live Virtual 2021, advanced practitioner experts reviewed clinical updates in the treatment of renal cell carcinoma, key patient counseling and monitoring considerations, and best practices to manage adverse events associated w...
Cholangiocarcinoma is a spectrum of invasive adenocarcinomas that arise in the intrahepatic, perihilar, or distal biliary tree, and is classified by location. During JADPRO Live Virtual 2021, Kristen O’Hagan, MSN, RN, ANP-BC, AOCNP®, dis...
Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS,...
Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)–modified T cells are a promising new treatment, and at ...
Recent advances have resulted in an expansion of treatment options for AML, especially targeted therapies and low-intensity regimens. At JADPRO Live Virtual 2021, presenters reviewed novel and targeted oral chemotherapy for adults with A...
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David ...
During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of p...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses key data from a session on hyper-CVAD and additional therapies for patients with acute lymphoblastic leukemia presented by Elias Jabbour,...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, distills information reviewed in the session on IDH-mutated acute myeloid leukemia presented by Courtney D. DiNardo, MD, MSCE, also of MD Anderson ...
Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, evaluates data from the session on p53 in myelodysplastic syndrome presented by David A. Sallman, MD, of H. Lee Moffitt Cancer Center and Research ...
Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews new therapeutic approaches in myelofibrosis presented in a session led by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2021 SOHO ...
Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews an update on treating Richter Syndrome, which was discussed in a session presented by Davide Rossi, MD, PhD, of Institute of Southern Switzerland, at the 2021 SOHO Annual M...
Lisa Nodzon PhD, APRN, AOCNP®, of Moffitt Cancer Center, reviews data on clinical trials and future directions in BCMA-directed CAR T cells presented in a session by Jesus G. Berdeja, MD, of Sarah Cannon Cancer Institute, at the 2021 SOH...
At the 2021 SOHO Annual Meeting, Maksim Mamonkin, PhD, of Baylor College of Medicine, reviewed progress in immunotherapy for T-cell lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses key insig...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, describes the clinical implications of novel agents for aggressive B-cell lymphoma, which were described at a session presented by Gilles Salles, MD, PhD, of Mem...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, evaluates novel treatment approaches in relapsed/refractory mantle cell lymphoma, as presented by Kami J. Maddocks, MD, of Ohio State University, at the 2021 SOH...
Sheeba Cantanelli, MPAS, PA-C, of UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, discusses results from studies evaluating adjuvant therapy with a PARP inhibitor in BRCA-mutated HER2-negative metastatic breast cance...
At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, a...
At JADPRO Live Virtual 2020, Casey Fazer-Posorske, PA-C, provided updates in the management of patients with head and neck cancer, including the types of head and neck cancers, their associated treatments and side-effect management, the ...
Presented by Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®
The treatment landscape of hepatocellular cancer has changed significantly within the past few years. At JADPRO Live Virtual 2020, Bridget O’Brien, DNP, APRN, FNP-BC, AOCNP®, provided an overview of developments in hepatocellular cancer ...
During JADPRO Live Virtual 2020, Kristen O’Hagan, ANP-BC, MS, AOCNP®, provided an overview of rare gastrointestinal tumors, their presentation, and current treatment algorithms. Ms. O’Hagan also discussed the advanced practitioner’s role...
At JADPRO Live Virtual 2020, Kathleen Burns, AGACNP-BC, OCN®, discussed strategies to track and treat symptoms associated with combination therapies for the treatment of renal cell carcinoma.
Presented by Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS
During JADPRO Live Virtual 2020, Cissimol Joseph, APRN, AOCNP®, and Prachee Singh, PA-C, MS, highlighted the clinical features and diagnostic workup of soft-tissue sarcoma and presented on a multidisciplinary approach to treatment planni...
During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, described personalization of the treatment of chronic lymphocytic leukemia (CLL) using molecular attributes of the disease, as well as patient characteristics. Dr. Kurtin...
Presented by Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®
At JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®, differentiated between AL and ATTR amyloidosis, discussed key considerations in selecting therapy, and identified wa...
Presented by Maritza Alencar, DNP, MBA, APRN-BC, BMTCN
During JADPRO Live Virtual 2020, Maritza Alencar, DNP, MBA, APRN-BC, BMTCN, described advances in the management and prevention of infectious disease complications and graft-vs.-host disease following transplant. Dr. Alencar also emphasi...
During JADPRO Live Virtual 2020, Ravi Krishnadasan, MD, FACP, provided an overview of the terminology of hemolysis, laboratory tests used in the diagnosis of hemolytic anemias, and appropriate indications for treatment of the various hem...
Presented by Val R. Adams, PharmD, FCCP, FHOPA, BCOP
During the JADPRO Live Virtual 2020 conference, Val R. Adams, PharmD, FCCP, FHOPA, BCOP, discussed how to determine which patients with cancer should be treated with direct oral anticoagulants (DOACs), the similarities and differences be...
Presented by Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
During the 2020 JADPRO Live Virtual conference, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, educated the audience on the most important causes of thrombocytopenia in hospitalized patients and diagnostic approaches to employ.
At JADPRO Live Virtual 2020, Veena Shankaran, MD, MS, reviewed data around the prevalence and risk factors for financial toxicity, discussed potential downstream consequences of financial toxicity in cancer care, and outlined four key st...
Presented by Kirollos S. Hanna, PharmD, BCPS, BCOP
During JADPRO Live Virtual 2020, Kirollos S. Hanna, PharmD, BCPS, BCOP, updated the audience on the pharmacology, new indications, and the clinical trial data of novel medications as well as expanded indications in solid tumors. Dr. Hann...
During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed ...
Presented by Sandra E. Kurtin,(1) PhD, ANP-C, AOCN®, Alyssa Henglefelt,(2) PharmD, BCOP, and Allyson Price,(3) MPAS, PA-C
The popular Biomarker Jeopardy session returned this year at JADPRO Live 2020. Sandra E. Kurtin, PhD, ANP-C, AOCN®, led the session, and was joined by Alyssa Henglefelt, PharmD, BCOP, and Allyson Price, PA-C. Using a Jeopardy format, the...
At JADPRO Live Virtual 2020, Lisa Kottschade, APRN, MSN, CNP, highlighted considerations for advanced practitioners on the recognition and monitoring of rare and life-threatening immune-related adverse events (irAEs), as well as strategi...
JADPRO Live 2020 was honored to have Dr. Richard Pazdur, the Director of the Oncology Center of Excellence at the FDA, discuss recent changes to oncology drug development and the approval process, the roles of the advanced practitioner i...
At JADPRO Live Virtual 2020, Brenda Martone, MSN, ANP-BC, AOCNP®, discussed treatment options available for advanced prostate cancer patients and the role of genetics and genomics in patients with advanced prostate cancer.
Presented by Gabrielle Zecha,(1) PA-C, MHA, Andrew S. Guinigundo,(2) MSN, RN, CNP, ANP-BC, David Johnson,(3) PA-C, and Sara Toth,(4) RN, APRN, FNP-C, AOCNP®, AGN-BC
JADPRO Live Virtual kicked off with the opening panel on advanced practitioner leadership during the COVID-19 pandemic. The group discussed their institutional emergency protocols, how they leveraged advanced practitioners (APs) to provi...
Presented by Laura J. Zitella,(1) MS, RN, ACNP-BC, AOCN®, and Tatiana M. Prowell,(2) MD
During JADPRO Live Virtual 2020, Conference Chair Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, spoke with Tatiana M. Prowell, MD, about overcoming implicit bias, the power of language, and creating a culture of respect in oncology for both ...
Presented by Jason Astrin, DMSc, MBA, PA-C, DFAAPA
At JADPRO Live Virtual 2020, Jason Astrin, DMSc, MBA, PA-C, DFAAPA, defined the concepts of productivity and value and discussed strategies for measuring the value of oncology advanced practitioners in order to recognize advanced practit...
Presented by Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC
During JADPRO Live Virtual 2020, Andrew S. Guinigundo, MSN, RN, CNP, ANP-BC, provided guidance to advanced practitioners on creating their elevator pitch and communicating their role.
Presented by Jessica Shank Coviello, DNP, APRN, ANP-BC, and Kejal Amin, PharmD, MBA, BCOP
Cardio-oncology is a rapidly emerging field, and advanced practitioners (APs) play key roles in the prevention, early detection, and optimal treatment of cardiotoxicities associated with cancer therapies. At JADPRO Live Virtual 2020, Jes...
During JADPRO Live Virtual 2020, Lorena A. Wright, MD, FACE, reviewed the principles of antihyperglycemic management and discussed the importance of working as a team to collaborate in the management of patients with cancer.
At the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, described the clinical implications of measuring minimal residual disease. Lisa Nodzon, Ph...
At the 2020 SOHO Annual Meeting, Alex F. Herrera, MD, of City of Hope, discussed the integration of novel agents into the management of patients with relapsed or refractory Hodgkin lymphoma. Kelly Valla, PharmD, BCOP, of Winship Cancer ...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses takeaways from the session on relapsed T-cell lymphoma led by Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, at the 2020 SOHO Annua...
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, considers exciting research on novel chimeric antigen receptor designs presented by Renier J. Brentjens, MD, PhD, of Memorial Sloan Kettering Cancer Center, at ...
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, summarizes the session on the genomics of drug response in acute lymphoblastic leukemia presented by Jun J. Yang, PhD, of St. Jude’s Research Hospital, at ...
In his keynote presentation, John DiPersio, MD, PhD, of Washington University, recipient of the SOHO 2020 Distinguished Lecturer Award, discussed immunotherapy for T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma. All...
Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, highlights implications for advanced practitioners from the presentation at the 2020 SOHO Annual Meeting by Guillermo Garcia-Manero, MD, also from MD Ander...
Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO...
Lisa Nodzon, PhD, APRN, AOCNP®, of Moffitt Cancer Center, discusses key points on the management of early relapse in multiple myeloma, a session presented at the 2020 SOHO Annual Meeting by Robert Z. Orlowski, MD, PhD, of The University...
Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was le...
Morgane C. Diven, PharmD, BCOP, of Phoenix VA Health Care System, breaks down abstract summaries published in The ASCO Post on a novel target, imaging agent, and androgen-deprivation therapy for prostate cancer, along with their implicat...
Following coverage from The ASCO Post, Jeannette Hammond, PA-C, of Seattle Cancer Care Alliance, comments on the results of practice-changing studies on novel therapies in urothelial cancer and renal cell carcinoma.
Following coverage by The ASCO Post, Laura Doherty, FNP-BC, AOCNP®, of Women & Infants Hospital of Rhode Island, interprets findings from major gynecologic oncology abstracts featured in The ASCO Post and considers takeaways for adva...
Paula Anastasia,(1) RN, MN, AOCN®, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®
Paula Anastasia, RN, MN, AOCN®, of UCLA Health Medical Center, and Wendy H. Vogel, MSN, FNP, AOCNP®, of Harborside, discuss results from studies evaluating therapies in women with de novo metastatic breast cancer and HER2-positive breast...
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, reviews the major abstracts in thoracic cancers from the ASCO20 Virtual Scientific Program using coverage by The ASCO Post and offers considerations for advanced ...
With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of Mayo Clinic, reviews clinical data on which patients with metastatic melanoma should receive combination therapy vs. single-agent PD-1 up front, and what to do at the ti...
Elizabeth S. Waxman,(1) RN, MSN, AOCN®, ANP-BC, and Abby Fuoto,(2) DNP, ANP-BC, AOCNP®, ACHPN
Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Center, evaluates a study showing activity by pralsetinib in patients with a variety of tumors harboring RET gene fusions, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, of ...
Amy Pierre,(1) MSN, ANP-BC, P. Andrew Allred,(2) MS, PA-C, and Allyson Price,(3) PA-C
Amy Pierre, MSN, ANP-BC, of Memorial Sloan Kettering Cancer Center, P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, and Allyson Price, PA-C, of MD Anderson Cancer Center, provide expert insights for advanced practitioner...
Josh Epworth, ARNP, of Seattle Cancer Care Alliance/University of Washington Medical Center, distills three influential abstracts from the ASCO virtual meeting and reflects on how advanced practitioners can use the findings to improve th...
Presented by Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite ...
Presented by Krista M. Rubin,(1) MS, FNP-BC, and Anthony J. Olszanski,(2) MD, RPh
At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based comb...
Presented by Joshua Bauml, MD, and Christina Knepley, CRNP
At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non–small cell lung cancer, including using biomarkers to guide treatment selection, understanding c...
Presented by Heather R. Greene, MSN, FNP, AOCNP®, and Lee S. Schwartzberg, MD, FACP
Heather R. Greene, MSN, FNP, AOCNP®, and Lee S. Schwartzberg, MD, FACP, discussed the current and future treatment landscape for triple-negative breast cancer, including recent and emerging data on approved treatments, novel therapeutic ...
Presented by Jame Abraham, MD, and Kelley D. Mayden, MSN, FNP, AOCNP®
Through expert, case-based discussion, Jame Abraham, MD, and Kelley Mayden, MSN, FNP, AOCNP®, presented existing and emerging data for current and investigational therapies for HER2-positive breast cancer and their associated adverse eve...
Presented by Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®
Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment.
Presented by Amanda M. Viereck, PA-C, and Anthony J. Olszanski, MD, RPh
Checkpoint inhibitors and oncolytic vaccine therapy have transformed the management of metastatic melanoma. This article presents the diagnosis and treatment landscape for metastatic melanoma, including clinicopathologic features of the ...
Presented by Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C
At JADPRO Live 2019, Petros Grivas, MD, PhD, and Jeannette Hammond, PA-C, reviewed data regarding mechanistic activity, efficacy, and safety of approved and emerging therapies for advanced or metastatic urothelial carcinoma, the selectio...
Presented by Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD
Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that incl...
Presented by Edward Libby,(1) MD, and Josh Epworth,(2) ARNP
Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minim...
Presented by Amy E. Pierre,(1) MSN, ANP-BC, and Joshua Richter,(2) MD
Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events,...
Presented by Lauren Held, PharmD, BCOP,(1) Sandra Kurtin,(2) PhD, ANP-C, AOCN®, and Lee Schwartzberg,(3) MD, FACP
This JADPRO Live session tested attendees’ knowledge on biomarkers and their use in determining targeted therapy for certain tumor types, key assays used to measure common biomarkers, and guideline-endorsed biomarker testing recommendati...
Presented by Patricia Mangan, RN, MSN, CRNP, and Edward Stadtmauer, MD
At JADPRO Live 2019, Patricia Mangan, RN, MSN, CRNP, and Edward Stadtmauer, MD, discussed the emerging world of chimeric antigen receptor (CAR) T-cell therapy, including the CAR T-cell process, approved indications and studies in hematol...
Presented by Kate Jeffers,(1) PharmD, MHA, BCOP, Megan May,(2) PharmD, BCOP, and Wendy H. Vogel,(3) MSN, FNP, AOCNP®
Presenters at JADPRO Live 2019 discussed the chemical and clinical nature of biosimilars, reviewed biosimilar development in oncology, and discussed implementation strategies for biosimilars.
Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe...
Presented by Sally Barbour, PharmD, BCOP, CPP, FHOPA
Sally Barbour, PharmD, BCOP, CPP, FHOPA, updated attendees on the FDA-approved therapies for initial or expanded indications for solid tumors across the past year, as well as their supporting clinical trial data and best practices for sa...
Presented by Leslie A. Swanson,(1) ARNP, and Kathleen Boyle,(2) PA-C
At JADPRO Live 2019, Leslie A. Swanson, ARNP, and Kathleen Boyle,PA-C, reviewed guideline-concordant molecular testing and therapy in patients with metastatic colorectal cancer (mCRC), the clinical significance of emerging data for exist...
Presented by Mazyar Shadman,(1,2) MD, MPH, and Amy Goodrich,(3) CRNP
Mazyar Shadman, MD, MPH, and Amy Goodrich, CRNP, reviewed data regarding the mechanistic activity, efficacy, and safety of approved and emerging therapeutic options for chronic lymphocytic leukemia (CLL) and strategies for managing adver...
Presented by Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP
Katherine L. Byar, MSN, ANP-BC, BMTCN®, and Matthew Lunning, DO, FACP, covered how to tackle challenges in the treatment of aggressive lymphomas by understanding how to apply emerging data, reviewing optimal therapies and treatment recom...
Following coverage by The ASCO Post, Jennifer L. Glass, PA-C, MS, of the Mayo Clinic dives into the major findings in prostate cancer from the 2019 ASCO Annual Meeting in Chicago and their implications for advanced practitioners.
Options for patients with non–small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. Elizabeth S. Waxman, RN, MSN, AOCN®, ANP-BC, of MD Anderson Cancer Cent...
In recent years, there has been an explosion of therapies for the treatment of melanoma, including BRAF mutation–guided therapy. With coverage by The ASCO Post, Lisa Kottschade, APRN, MSN, CNP, of the Mayo Clinic reviews clinical data su...
Amy Hacker-Prietz, (1) MS, PA-C, Abby Fuoto, (2) DNP, ANP-BC, AOCNP®, ACHPN, Nanette Fong, (3) RN, MSN, and P. Andrew Allred, (4) MS, PA-C
Trials studying additional solid cancers, such as pancreatic cancer, head and neck cancer, glioblastoma, and glioma are reviewed in this section and accompanied by advanced practitioner commentaries. In addition, a study exploring the be...
Several abstracts presented at the ASCO Annual Meeting reflected the meeting theme of providing high-quality care to every patient. Following coverage by The ASCO Post, Editor-in-Chief to JADPRO, Pamela Hallquist Viale, RN, MS, CNS, ANP,...
Using coverage from The ASCO Post of the ASCO Annual Meeting, Carolyn Grande, CRNP, AOCNP®, of the University of Pennsylvania Health System evaluates study findings in gastrointestinal cancer and discusses what advanced practitioners sho...
Jeannette Hammond, PA-C, of the Seattle Cancer Care Alliance comments on major research presented at the ASCO Annual Meeting: a study addressing an unmet need in the metastatic urothelial cancer setting, a study showing no benefit from a...
Laura Doherty, FNP-BC, AOCNP®, of the Women & Infants Hospital of Rhode Island offers commentary on major gynecologic cancer abstracts featured from the ASCO Annual Meeting by The ASCO Post, including findings in carcinosarcoma of th...
Amy Pierre, MSN, ANP-BC, and Nancy M. Nix, PharmD, BCPS, BCOP
Amy Pierre, MSN, ANP-BC, of the Memorial Sloan Kettering Cancer Center, and Nancy M. Nix, PharmD, BCPS, BCOP of St. Joseph’s/Candler Health System offer an advanced practitioner perspective on trials assessing the efficacy and safety of ...
Wendy H. Vogel, MSN, FNP, AOCNP®, of Wellmont Cancer Institute discusses results from a study in hormone receptor–positive metastatic breast cancer (MONALEESA-7), two studies in the metastatic HER2-positive setting (SOPHIA and NALA), as ...
New oncology approvals from 2017 to 2018 were mostly for additional indications, with many agents moved up to first-line therapy. Patrick J. Kiel, PharmD, BCPS, BCOP, detailed their implications for advanced practice.
Presented by Rebecca J. Nelson, PharmD, BCOP, Dr. Nelson discussed the pharmacology and indications of medications approved from 2017 to 2018 for the management of patients with hematologic malignancies.
According to Rowena Schwartz, PharmD, BCOP, it is important to consider broad treatment options, both direct oral anticoagulants and older agents such as heparin, when treating patients with venous thromboembolism, as the newer agents ma...
Presented by Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C
Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C, reviewed landmark clinical trials of adjuvant therapies for women with HER2–positive breast cancer and emphasized the key role of advanced practitioners in managing adverse eve...
At JADPRO Live 2018, Sherry Goldman, MSN, NP, CBCN, delved into different surgical rationales for lumpectomy, mastectomy, and mastectomy with reconstructions. Ms. Goldman also explored the benefits and disadvantages associated with nippl...
Presented by Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP
Advanced practitioners play an important role in recognizing and treating adverse events caused by multimodality therapies in lung cancer. Marianne Davies, DNP, RN, CNS, ACNP, AOCNP®, and Beth Eaby-Sandy, MSN, CRNP, detailed strategies f...
Presented by Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD
Lisa A. Kottschade, APRN, MSN, CNP, and Svetomir N. Markovic, MD, PhD, shared clinical data supporting the use of emerging targeted therapies and immunotherapies in the treatment of metastatic melanoma.
Presented by Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN
HPV-related head and neck cancer is emerging as an epidemic in the US population. At JADPRO Live, Julie E. Bauman, MD, MPH, and Abby Fuoto, DNP, ANP-BC, AOCNP®, ACHPN, evaluated risk factors and prevention strategies. They also discussed...
Presented by Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD
Laura Doherty, FNP-BC, AOCNP®, and Katina Robison, MD, discussed the indications for the three PARP agents (olaparib, rucaparib, and niraparib) and strategies for managing PARP inhibitor–related side effects.
Presented by Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®
Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®, explained the use of tyrosine kinase inhibitors in the adjuvant setting in patients with advanced renal cell carcinoma, as well has how to best utilize immunotherapy in this set...
Presented by Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®
Several targeted agents have recently emerged for the treatment chronic lymphocytic leukemia and follicular lymphoma, which has made treatment selection more complex. Philip A. Thompson, MB, BS, and Lisa Nodzon, PhD, ARNP, AOCNP®, descri...
Presented by Amy Goodrich, CRNP, and Jose D. Sandoval-Sus, MD
Thanks to the introduction of checkpoint inhibitors, patients with classical Hodgkin lymphoma have a better chance at living longer with the disease. However, treatment-related side effects can impact quality of life in the short- and lo...
Presented by Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD
New agents for the treatment of myeloma have individual and class effects that advanced practitioners need to know about when helping to keep their patients on treatment regimens. At JADPRO Live, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, an...
Presented by Jae Park, MD, and Amber C. King, PharmD, BCOP
Jae Park, MD, and Amber C. King, PharmD, BCOP, shared background and clinical information regarding CAR T-cell therapy in acute lymphoblastic leukemia and large-cell lymphoma, as well as strategies to mitigate cytokine release syndrome a...
Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD
Sandra E. Kurtin, PhD, ANP-C, AOCN®, and Jennifer Knight, MD, provided advice to the advanced practitioner audience on appropriately applying diagnostic tests in order to acquire actionable information about a patient’s disease.
Presented by Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP
Acute myeloid leukemia (AML) is diagnosed in about 20,000 people a year and remains a very challenging malignancy to treat. Kelda Gardner, PA-C, MHS, and Melinda Tran, PharmD, BCOP, reviewed the basics of treating AML, including new asse...
Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on...
FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these d...
Immunotherapy has proven activity in several types of cancer; however, the mechanisms of action of immunotherapy can cause several different immune-related toxicities. Advanced practitioners are in a unique position to recognize the timi...
Neratinib following the completion of trastuzumab has been shown to reduce the risk of disease recurrence for patients with HER2-positive early breast cancer in whom extended adjuvant therapy seems advisable. In clinical trials, the most...
Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ...
Lynch syndrome is the most common inherited form of colorectal cancer, affecting approximately 1 in 279 individuals, or 1.2 million people in the United States. It's also associated with a predisposition to endometrial, ovarian, and stom...
For more than 30 years, there were no new treatments in bladder cancer. Then, in 2016, there were five drug approvals. JADPRO Live presenters delved into recent advancements and opportunities for improving outcomes for patients with blad...
A multidisciplinary team can help improve the outcomes of patients with any cancer, but particularly so for patients with soft-tissue sarcomas, as discussed at JADPRO Live. During this presentation, MD, PA, and NP colleagues from Moffitt...
The treatment landscape for multiple myeloma is rapidly changing. At JADPRO Live 2017, presenters brought advanced practitioners up to date on the newest approaches to the management of this disease, as well as what to be aware of when t...
Acute myeloid leukemia is a disease that affects predominantly older patients, with a median age at diagnosis of 68. Overall prognosis is poor, but novel therapies that have emerged in recent years offer hope that outcomes can improve. I...
Identifying key molecular attributes can help in the risk-adapted treatment of Hodgkin lymphoma and chronic lymphocytic leukemia. At JADPRO Live, presenters reviewed best practices for managing patients with the rapidly expanding armamen...
There have been promising results from clinical trials on the efficacy of engineering patients' immune cells to treat their cancers. CAR T-cell therapy also has unique toxicities advanced practitioners should be aware of.
The addition of radiation to preoperative chemotherapy and newer therapeutic combinations add to treatment options for these difficult-to-treat cancers.
Novel therapies are changing the treatment paradigm for both melanoma and advanced/metastatic basal cell carcinoma. While immunotherapies are increasing survival benefits in melanoma, they are associated with unique immune-related advers...
Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and ma...
Multidisciplinary clinics for pancreatic cancer such as one established at Johns Hopkins offer advantages in the care of patients with pancreatic cancer. Advanced practitioners can play a role in multidisciplinary care, providing symptom...
Head and neck cancer care is complex, and there are limited treatment options; over the past decade only one new therapy received FDA approval. However, as in other tumor types, the landscape is changing with the recent emergence of newe...
Following years in which there were only modest gains in treatment options for non-small cell lung cancer, recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions.
Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, there is a need for advanced practitioners to stay up to date and info...
Treatment for both Hodgkin and Non-Hodgkin lymphoma now includes chemotherapy, targeted therapy, and new immunotherapies. As research continues to shine the light on tumor genetics, clinical variability, and new treatment approaches, adv...
Even though multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions and the management of toxicities related to newer dru...
As antibiotic resistant bacteria are becoming ubiquitous, managing infection becomes more complex. Optimizing preventive measures, early diagnosis, and management of infection is of the highest priority in cancer care.
Advanced practitioners are an integral part of the cancer care team. Therefore, it is imperative they are knowledgeable of risk factors associated with venous thromboembolism in the oncology setting, including signs or symptoms and manag...
Despite advances in the management of chemotherapy-induced nausea and vomiting (CINV), clinical management remains a challenge and CINV continues to be a side effect that patients fear most. Advanced practitioners can play a major role i...
These three reports (on pages 211–216) are from the 2011 National Comprehensive Cancer Network® (NCCN®) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™, a meeting held on March 9–13, 2011, in Hollywood, Flori...
These four reports (from page 55–62) are from the 2010 National Comprehensive Cancer Network (NCCN) Nursing Program: Role of the Advanced Practice Nurse in Quality Cancer Care™, a meeting held on March 10, 2010, in Hollywood, Florida. Re...
